Penny Stock Under Rs 15 Locked in the 5 Per Cent Upper Circuit Secures Rs 85.6 Crore Export Orders
The stock has delivered multibagger returns of 160.24 per cent over the past year, and a 62.2 per cent return over three years.
Welcure Drugs & Pharmaceuticals Limited, a Small-Cap pharmaceutical company, has announced the receipt of two major export sourcing orders valued at Rs 85.6 crore. These orders have come from Giant Exim and Ravina International, involving the procurement and consolidation of mycorrhizal inoculant. Importantly, these transactions are structured as fee-based activities, meaning Welcure will earn commission income without any inventory or logistics-related risks. This move is expected to enhance the company’s margins for the current quarter, with revenue being recognized upon dispatch of each lot.
DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, download the service details here.
Additionally, Welcure is in advanced talks with international buyers for similar export mandates and expects to finalize further orders worth over Rs 20 crore during the ongoing quarter. The company has clarified that these transactions are part of its regular business operations and do not fall under related-party transactions as per SEBI regulations. Welcure is also focused on expanding its fee-based export business while continuing to maintain a debt-free capital structure.
As of June 30, 2025, Welcure’s stock is trading at Rs 13.6, with a 52-week high of Rs 15.89 and a low of Rs 5.02. The stock has delivered multibagger returns of 160.24 per cent over the past year, and a 62.2 per cent return over three years. It has a market capitalization of Rs 146 crore and a price-earnings ratio of 32.72. The company is backed by notable public shareholders including Manish Rajput and Rahul Ratansingh Sikarwar (each holding 9.78%) and Akshay Nadiya, Kuldeep Ranvirsingh Tomar, and Tatad Nayan Gautambhai (each with 8.89%).
Founded in 1992, Welcure specializes in the manufacturing and marketing of pharmaceutical formulations, such as tablets, capsules, and therapeutic drugs including antibiotics and anti-diabetics. However, the company has been posting losses for several years, resulting in a complete halt in its business operations. Efforts are currently underway to revive its business through potential partnerships or financial collaborations. The primary source of income remains commission-based revenue. The recent management changes include the appointment of Mr. Vishal Mehra as CFO in September 2022 and the resignation of MD Mr. Sudhir Chandra in October 2022.
Disclaimer: The article is for informational purposes only and not investment advice.